Skip to main content
Premium Trial:

Request an Annual Quote

Piet Houwen, Dirk Zimmermann, Hilde Eylenbosch

Biocartis has announced several changes to its management team. The firm has appointed Piet Houwen as its chief operating officer earlier this month. Prior to joining Biocartis, Houwen served as COO at Ablynx. Before Ablynx, he held global roles for Sanofi/Genzyme and Janssen Pharmaceutica (part of Johnson & Johnson family of companies).

Biocartis has also appointed Dirk Zimmermann as its global head pharma collaborations and partnering. Zimmerman will assume the position at the firm in May. Prior to joining Biocartis, Zimmermann held positions at Roche Diagnostics and Qiagen in product development and corporate venturing.

Biocartis has also let go of Hilde Eylenbosch as the firm's chief commercial officer, effective at the end of April. The firm does not have plans to immediately appoint a new CCO, as it will redistribute the tasks to the company's CEO and senior commercial management.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.